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To the editor: 
We read with great interest the editorial by Hedenstierna et al.1 on the recent World Health 
Organization (WHO) guidelines for the prevention of surgical site infections (SSIs). Some of the issues 
raised have been already addressed in Lancet Infectious Diseases in response to previous 
comments.2,3 
It is important to note that guidelines developed by WHO are not based simply on meta-analyses, as 
suggested by Hedenstierna et al. Rather, WHO uses the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) approach to rate the quality of a body of evidence and to 
produce information that is used by guideline panels to formulate recommendations. This includes 
carefully considering the balance of benefits and harms and aspects related to patient values and 
preferences, resource implications, feasibility, and acceptability.4 The guideline panels are composed 
of international experts from several countries and with different professional and cultural 
backgrounds.5 Through this process, the issues raised by Hedenstierna et al. were examined, and the 
panel consensus deemed it appropriate to formulate a recommendation for this intervention. 
Hedenstierna et al. argue that the administration of an 80% fraction of inspired oxygen (Fio2) in 
surgical patients does not lead to a reduced risk of SSIs. Our meta-analysis of all available 
randomized controlled studies at that time (n = 15) indicated that 80% Fio2 may reduce SSI 
incidence.6 However, there was substantial clinical and statistical heterogeneity in the studies, and 
the 95% CI included no effect (odds ratio [OR] 0.84; 95% CI, 0.66 to 1.06). Upon detailed review, the 
guideline panel reasoned that an important portion of the heterogeneity was related to differences 
in the patient population characteristics and delivery of the intervention. Subsequently, subgroup 
and metaregression analyses were done to investigate the sources of the heterogeneity. These 
analyses showed robust evidence for a reduction of SSIs in patients under general anesthesia with 
endotracheal intubation receiving 80% Fio2, and the panel decided that this intervention should be 
recommended for this group (OR: 0.72; 95% CI, 0.55 to 0.94). We emphasize that the 
recommendation is not only based on this subgroup, it is strictly limited to it. There is no 
generalization of this recommendation to other patients, unlike the recently published 
recommendations by the American College of Surgeons and Surgical Infection Society, who 
recommend it for all patients undergoing general anesthesia.7 Of note, the WHO recommendation 
for this group of patients was recently echoed in the Centers for Disease Control and Prevention 
guideline for the prevention of SSIs.8 
Hedenstierna et al. are concerned about the lack of “solid and large trials.” We agree that such trials 
would have made the panel’s task easier, but in their absence, the panel had to make 
recommendations based on the best available evidence from smaller trials. The combined sample 
size from these trials exceeded the optimal information size by a large margin, and there was thus 
no serious imprecision.9 Of note, the largest trial included more than 2,000 patients and showed a 
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statistically significant reduction in SSIs.10 Hedenstierna et al. suggest that if we had excluded this 
study, which used 70% nitrous oxide (N2O) in place of oxygen in the control group, the effect would 
no longer be statistically significant. Excluding this trial post hoc would be inappropriate because it 
met all the inclusion criteria of the systematic review. To address the concerns raised, we conducted 
a subgroup analysis of trials without the use of N2O. The estimate from these trials was in line with 
the overall effect (OR 0.74; 95% CI, 0.58 to 0.95), and there was no evidence for modification of the 
effect of 80% Fio2 dependent on whether or not patients received N2O. The results from all other 
trials were compatible with a reduction in SSIs, except for one small outlying trial.11 There was little 
evidence that results differed between trials at higher and lower risk of bias, and risk of bias was 
generally low. 
The study by Kurz et al.12 was not included because it was published outside the predetermined time 
period of our review. We included this study in a post facto analysis, and we found little effect on 
the estimates: OR 0.75 (95% CI, 0.59 to 0.96) including the Kurz et al. study versus OR 0.72 (95% CI, 
0.55 to 0.94) when excluding it. 
The editorialists also expressed concern about potential harms of hyperoxia. However, the literature 
cited in support of these concerns is based on evidence from settings that differ from the routine 
clinical settings our recommendations relate to, for example, intensive care units or an animal 
model.1 In the review of studies used for our analysis, which included more than 5,000 patients, no 
evidence of excess pulmonary dysfunction (atelectasis, pneumonia) was found in the groups of 
patients treated with 80% Fio2. Furthermore, the WHO guidelines state that patients with chronic 
lung disease were excluded from most trials, and therefore our recommendation does not apply to 
these patients. 
Finally, Hedenstierna et al. used unfortunate language suggesting that we advocated for in-hospital 
production of oxygen, which would be a gross misrepresentation of the WHO guidelines. The 
guidelines highlight that the production or procurement of oxygen is an additional cost for the 
healthcare facility or patient in resource-limited settings. We did not suggest, nor intend to suggest, 
that oxygen local production should be given priority in low-income countries. Several panel 
members from low- and middle-income countries contributed to formulating the text and were 
confident that the guidelines adequately informed decision-makers in resource-limited settings. 
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